Review Article
Oral Fosfomycin for the Treatment of Acute and Chronic Bacterial Prostatitis Caused by Multidrug-Resistant Escherichia coli
Table 3
Fosfomycin (FOS) treatment for acute and chronic bacterial prostatitis caused by antimicrobial-resistant E. coli.
| Reference | Subject number | Type of bacterial prostatitisa | Age | Susceptibility | FOS MIC | MDRd mechanism | FT e dosage regimen | FT treatment duration | Microbiological eradication | Clinical cure | CIPb | TMP-SMXc |
| [7] | 1 | C | 80 | Rg | R | — | AmpC | 3 g·q 72 h | 6 weeks | Yes | Yes | 2 | C | 52 | R | R | — | ESBLi | 3 g·q 72 h | 6 weeks | Yes | Yes | 3 | C | 54 | R | S | — | ESBL | 3 g·q 72 h | 6 weeks | No | No | 4 | C | 54 | R | R | — | — | 3 g·q 72 h | 6 weeks | No | No | 5 | C | 31 | R | S | — | — | 3 g·q 72 h | 6 weeks | No | No | 6 | C | 29 | Sh | S | — | ESBL | 3 g·q 72 h | 6 weeks | Yes | Yes | 7 | C | 57 | R | R | — | — | 3 g·q 72 h | 6 weeks | Yes | Yes | 8 | C | 22 | R | R | — | — | 3 g·q 72 h | 6 weeks | Yes | Yes | 9 | C | 44 | S | R | — | — | 3 g·q 72 h | 6 weeks | No | No | 10 | C | 59 | R | S | — | ESBL | 3 g·q 72 h | 6 weeks | Yes | Yes | 11 | C | 49 | R | R | — | — | 3 g·q 72 h | 6 weeks | Yes | No | 12 | C | 70 | R | S | — | — | 3 g·q 72 h | 6 weeks | No | No | 13 | C | 65 | S | S | — | — | 3 g·q 48 h | 6 weeks | No | No | 14 | C | 54 | S | S | — | — | 3 g·q 48 h | 6 weeks | Yes | Yes | [24] | 1 | A/C | 73 | R | — | 1 μg/mL | ESBL | 3 g OD/BID | 16 weeks | Yes | Yes | 2 | A | 80 | R | — | 1 μg/mL | ESBL | 3 g OD | 12 weeks | Yes | Yes | [22] | 1 | C | 53 | R | — | 2 μg/mL | ESBL | 3 g·q 72 h | 2 weeks | Yes | Yes | [25] | 13 total | C | 53.6f | 8/13 R | 7/13 R | 13/13 S | 2/13 ESBL | 3 g OD q 48 h | 7 weeks | — | ∼77% |
|
|
aA, acute prostatitis; C, chronic prostatitis; U, unspecified; bCIP, ciprofloxacin; cTMP-SMX, trimethoprim-sulfamethoxazole; dMDR, multidrug-resistant; eFT, fosfomycin tromethamine; fmean age (years); gR, resistant; hS, susceptible; iESBL, extended-spectrum β-lactamase; jMBL, metallo- β-lactamase; combination therapy of oral FT (3 g q 72 h) and oral doxycycline (100 mg q 12 h). |